Chronic Disease

Reports of high-impact chronic disease studies by medical professionals

Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for...

1. At week 48, there was a similar proportion of participants with plasma HIV-1 RNA ≥ 50 copies per mL between the 8-week and...

Special Report: Vaccines in Development Part 5: Potential emerging vaccine candidates and other considerations

Section 5: Other Promising Vaccine Candidates and Considerations Messenger RNA (mRNA) vaccines have offered a novel methodology in the context of COVID-19, including the Pfizer/BioNTech1...

COVID-19 susceptibility may be increased in patients with hematological malignancies compared to solid organ...

1. Patients with hematological malignancies were found to be at an increased risk of COVID-19 and were more likely to require admission to the...

Special Report: Vaccines in Development Part 4: Johnson & Johnson vaccine as another frontrunner

Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its...

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

1. Older age, progressive disease status, diagnosis of acute myeloid leukemia, non-Hodgkin lymphoma, or plasma cell neoplasms, and severe or critical COVID-19 at admission...

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes With many COVID-19 vaccine being studied and approved for emergency use, one important candidate is...

ECMO-facilitated resuscitation may improve survival compared to ACLS in patients with out-of-hospital cardiac arrests

1. Survival to hospital discharge was higher among patients in the ECMO-facilitated resuscitation group versus those receiving ACLS resuscitation. 2. Patients who received early ECMO...

Ticagrelor non-superior to clopidogrel in the reduction of PCI-related myocardial necrosis

1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with...

Association between low density lipoprotein and all cause and cause specific mortality in Denmark

1. There is a U-shaped association of LDL-C levels and risk of all-cause mortality with the lowest risk at LDL-C levels of 3.6 and...

Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to...

 1. Febuxostat was non-inferior to allopurinol for primary cardiovascular endpoints including hospitalization for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome, non-fatal stroke, or...

All-time hits